Thomas Duning's research while affiliated with Klinikum Bremen-Ost and other places

What is this page?


This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.

It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.

If you're a ResearchGate member, you can follow this page to keep up with this author's work.

If you are this author, and you don't want us to display this page anymore, please let us know.

Publications (24)


Woher kommen die Demenzsymptome?
  • Article

April 2024

·

1 Read

·

1 Citation

InFo Neurologie + Psychiatrie

Thomas Duning
Share







PRISMA flow diagram of the literature search of this systematic review. Adapted from Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. Creative Commons.⁴¹
Ginkgo biloba Extract EGb 761 in the Treatment of Patients with Mild Neurocognitive Impairment: A Systematic Review
  • Literature Review
  • Full-text available

March 2023

·

42 Reads

·

9 Citations

Neuropsychiatric Disease and Treatment

Neuropsychiatric Disease and Treatment

Background Many clinical trials testing Ginkgo biloba extract EGb 761 in patients with mild forms of cognitive impairment were conducted before widely accepted terms and diagnostic criteria for such conditions were available. This makes it difficult to compare any results from earlier and more recent trials. The objective of this systematic review was to provide a descriptive overview of clinical trials of EGb 761 in patients who met the diagnostic criteria for mild neurocognitive disorder (mild NCD) according to the Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5). Methods MEDLINE, PubMed and EMBASE were searched for randomized, placebo-controlled double-blind trials of EGb 761 in mild impairment of cognitive functioning. All trials involving patients who met retrospectively applied diagnostic criteria for mild NCD were included. Trials of primary prevention of dementia and trials of combinations of medical treatments were excluded. Results Among 298 records found in databases and 76 further records related to EGb 761 in references of systematic reviews, 9 reports on clinical trials involving 946 patients met the pre-specified criteria for inclusion. Beneficial effects of EGb 761 were seen in neuropsychological tests (8 of 9 studies), scales for neuropsychiatric symptoms (3 of 3 studies), geriatric rating scales (1 of 2 studies) and global ratings of change (1 of 1 study). Significant effects were found in several domains of cognition (memory, speed of processing, attention and executive functioning). Among the neuropsychiatric symptoms, depression (2 of 3 studies) and anxiety (1 of 1 study) were significantly improved. No differences between EGb 761 treatment and placebo were seen with regard to the rates of adverse events. Discussion The included studies demonstrate treatment benefits of Ginkgo biloba extract EGb 761, mainly on cognitive deficits and neuropsychiatric symptoms, in patients with mild NCD. The drug was safe and well tolerated.

Download



Citations (2)


... The supplement has reported neuroprotective benefits owing to its modulatory effects on tau protein phosphorylation, amyloidogenesis, and mitochondrial function, as well as antiapoptotic, anti-inflammatory, and antioxidant properties [62]. Clinical studies regarding the effectiveness of ginkgo in improving memory, attention and concentration, depression, anxiety, and fatigue have yielded mixed results overall [62,63]. There are no known reports of hepatic benefits or ginkgo-induced liver failure in humans. ...

Reference:

Herbal and Non-Herbal Dietary Supplements for Psychiatric Indications: Considerations in Liver Transplantation
Ginkgo biloba Extract EGb 761 in the Treatment of Patients with Mild Neurocognitive Impairment: A Systematic Review
Neuropsychiatric Disease and Treatment

Neuropsychiatric Disease and Treatment

... The intersection of POD and CSDH, both age-related conditions, presents significant clinical challenges. Recent trends focus on preventive measures for POD, ranging from pharmacological methods like dexmedetomidine sedation and antipsychotic treatments to holistic, multi-component interventions and innovative non-pharmacological strategies led by occupational therapy teams [28,29]. ...

Postoperative delirium – treatment and prevention
  • Citing Article
  • December 2020

Current Opinion in Anaesthesiology